List view / Grid view

Dr Vincent Blomen (Senior Director of Discovery Sciences at Scenic Biotech)

 

news

Targeting PLA2G15 to treat neurometabolic disorders

Scenic Biotech and Stanford University have published a study identifying…

20 May 2025 | By

Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.